Illinois General Assembly - Full Text of HB4300
Illinois General Assembly

Previous General Assemblies

Full Text of HB4300  94th General Assembly

HB4300 94TH GENERAL ASSEMBLY


 


 
94TH GENERAL ASSEMBLY
State of Illinois
2005 and 2006
HB4300

 

Introduced 12/21/05, by Rep. Chapin Rose

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/201   from Ch. 56 1/2, par. 1201
720 ILCS 570/206   from Ch. 56 1/2, par. 1206
720 ILCS 570/218 new

    Amends the Illinois Controlled Substances Act. Provides that a drug product containing dextromethorphan may not be sold, delivered, distributed, or possessed except in accordance with the prescription requirements of the Act. Provides that a violation is a Class 4 felony. Exempts from this requirement a drug product containing dextromethorphan that is sold in tablet, liquid, capsule, or gel form and which is formulated, packaged, and sold in dosages and concentrations for use as an over-the-counter cough and cold medicine.


LRB094 12962 RLC 47811 b

CORRECTIONAL BUDGET AND IMPACT NOTE ACT MAY APPLY

 

 

A BILL FOR

 

HB4300 LRB094 12962 RLC 47811 b

1     AN ACT concerning criminal law.
 
2     Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
 
4     Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 201 and 206 and by adding Section
6 218 as follows:
 
7     (720 ILCS 570/201)  (from Ch. 56 1/2, par. 1201)
8     Sec. 201. (a) The Department shall carry out the provisions
9 of this Article. The Department or its successor agency may add
10 substances to or delete or reschedule all controlled substances
11 in the Schedules of Sections 204, 206, 208, 210 and 212 of this
12 Act. In making a determination regarding the addition,
13 deletion, or rescheduling of a substance, the Department shall
14 consider the following:
15         (1) the actual or relative potential for abuse;
16         (2) the scientific evidence of its pharmacological
17     effect, if known;
18         (3) the state of current scientific knowledge
19     regarding the substance;
20         (4) the history and current pattern of abuse;
21         (5) the scope, duration, and significance of abuse;
22         (6) the risk to the public health;
23         (7) the potential of the substance to produce
24     psychological or physiological dependence;
25         (8) whether the substance is an immediate precursor of
26     a substance already controlled under this Article;
27         (9) the immediate harmful effect in terms of
28     potentially fatal dosage; and
29         (10) the long-range effects in terms of permanent
30     health impairment.
31     (b) (Blank).
32     (c) (Blank).

 

 

HB4300 - 2 - LRB094 12962 RLC 47811 b

1     (d) If any substance is scheduled, rescheduled, or deleted
2 as a controlled substance under Federal law and notice thereof
3 is given to the Department, the Department shall similarly
4 control the substance under this Act after the expiration of 30
5 days from publication in the Federal Register of a final order
6 scheduling a substance as a controlled substance or
7 rescheduling or deleting a substance, unless within that 30 day
8 period the Department objects, or a party adversely affected
9 files with the Department substantial written objections
10 objecting to inclusion, rescheduling, or deletion. In that
11 case, the Department shall publish the reasons for objection or
12 the substantial written objections and afford all interested
13 parties an opportunity to be heard. At the conclusion of the
14 hearing, the Department shall publish its decision, by means of
15 a rule, which shall be final unless altered by statute. Upon
16 publication of objections by the Department, similar control
17 under this Act whether by inclusion, rescheduling or deletion
18 is stayed until the Department publishes its ruling.
19     (e) The Department shall by rule exclude any non-narcotic
20 substances from a schedule if such substance may, under the
21 Federal Food, Drug, and Cosmetic Act, be lawfully sold over the
22 counter without a prescription.
23     (f) The sale, delivery, distribution, and possession of a
24 drug product containing dextromethorphan shall be in
25 accordance with Section 218 of this Act. Dextromethorphan shall
26 not be deemed to be included in any schedule by reason of
27 enactment of this title unless controlled after the date of
28 such enactment pursuant to the foregoing provisions of this
29 section.
30     (g) Authority to control under this section does not extend
31 to distilled spirits, wine, malt beverages, or tobacco as those
32 terms are defined or used in the Liquor Control Act and the
33 Tobacco Products Tax Act.
34 (Source: P.A. 91-714, eff. 6-2-00.)
 
35     (720 ILCS 570/206)  (from Ch. 56 1/2, par. 1206)

 

 

HB4300 - 3 - LRB094 12962 RLC 47811 b

1     Sec. 206. (a) The controlled substances listed in this
2 Section are included in Schedule II.
3     (b) Unless specifically excepted or unless listed in
4 another schedule, any of the following substances whether
5 produced directly or indirectly by extraction from substances
6 of vegetable origin, or independently by means of chemical
7 synthesis, or by combination of extraction and chemical
8 synthesis:
9         (1) Opium and opiates, and any salt, compound,
10     derivative or preparation of opium or opiate, excluding
11     apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
12     nalmefene, naloxone, and naltrexone, and their respective
13     salts, but including the following:
14             (i) Raw Opium;
15             (ii) Opium extracts;
16             (iii) Opium fluid extracts;
17             (iv) Powdered opium;
18             (v) Granulated opium;
19             (vi) Tincture of opium;
20             (vii) Codeine;
21             (viii) Ethylmorphine;
22             (ix) Etorphine Hydrochloride;
23             (x) Hydrocodone;
24             (xi) Hydromorphone;
25             (xii) Metopon;
26             (xiii) Morphine;
27             (xiv) Oxycodone;
28             (xv) Oxymorphone;
29             (xvi) Thebaine;
30             (xvii) Thebaine-derived butorphanol.
31             (xviii) Dextromethorphan subject to Section 218 of
32         this Act.
33         (2) Any salt, compound, isomer, derivative or
34     preparation thereof which is chemically equivalent or
35     identical with any of the substances referred to in
36     subparagraph (1), but not including the isoquinoline

 

 

HB4300 - 4 - LRB094 12962 RLC 47811 b

1     alkaloids of opium;
2         (3) Opium poppy and poppy straw;
3         (4) Coca leaves and any salt, compound, isomer, salt of
4     an isomer, derivative, or preparation of coca leaves
5     including cocaine or ecgonine, and any salt, compound,
6     isomer, derivative, or preparation thereof which is
7     chemically equivalent or identical with any of these
8     substances, but not including decocainized coca leaves or
9     extractions of coca leaves which do not contain cocaine or
10     ecgonine (for the purpose of this paragraph, the term
11     "isomer" includes optical, positional and geometric
12     isomers);
13         (5) Concentrate of poppy straw (the crude extract of
14     poppy straw in either liquid, solid or powder form which
15     contains the phenanthrine alkaloids of the opium poppy).
16     (c) Unless specifically excepted or unless listed in
17 another schedule any of the following opiates, including their
18 isomers, esters, ethers, salts, and salts of isomers, whenever
19 the existence of these isomers, esters, ethers and salts is
20 possible within the specific chemical designation, dextrorphan
21 excepted:
22         (1) Alfentanil;
23         (1.1) Carfentanil;
24         (2) Alphaprodine;
25         (3) Anileridine;
26         (4) Bezitramide;
27         (5) Bulk Dextropropoxyphene (non-dosage forms);
28         (6) Dihydrocodeine;
29         (7) Diphenoxylate;
30         (8) Fentanyl;
31         (9) Sufentanil;
32         (9.5) Remifentanil;
33         (10) Isomethadone;
34         (11) Levomethorphan;
35         (12) Levorphanol (Levorphan);
36         (13) Metazocine;

 

 

HB4300 - 5 - LRB094 12962 RLC 47811 b

1         (14) Methadone;
2         (15) Methadone-Intermediate,
3     4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
4         (16) Moramide-Intermediate,
5     2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
6     acid;
7         (17) Pethidine (meperidine);
8         (18) Pethidine-Intermediate-A,
9     4-cyano-1-methyl-4-phenylpiperidine;
10         (19) Pethidine-Intermediate-B,
11     ethyl-4-phenylpiperidine-4-carboxylate;
12         (20) Pethidine-Intermediate-C,
13     1-methyl-4-phenylpiperidine-4-carboxylic acid;
14         (21) Phenazocine;
15         (22) Piminodine;
16         (23) Racemethorphan;
17         (24) Racemorphan;
18         (25) Levo-alphacetylmethadol (some other names:
19     levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
20     (d) Unless specifically excepted or unless listed in
21 another schedule, any material, compound, mixture, or
22 preparation which contains any quantity of the following
23 substances having a stimulant effect on the central nervous
24 system:
25         (1) Amphetamine, its salts, optical isomers, and salts
26     of its optical isomers;
27         (2) Methamphetamine, its salts, isomers, and salts of
28     its isomers;
29         (3) Phenmetrazine and its salts;
30         (4) Methylphenidate.
31     (e) Unless specifically excepted or unless listed in
32 another schedule, any material, compound, mixture, or
33 preparation which contains any quantity of the following
34 substances having a depressant effect on the central nervous
35 system, including its salts, isomers, and salts of isomers
36 whenever the existence of such salts, isomers, and salts of

 

 

HB4300 - 6 - LRB094 12962 RLC 47811 b

1 isomers is possible within the specific chemical designation:
2         (1) Amobarbital;
3         (2) Secobarbital;
4         (3) Pentobarbital;
5         (4) Pentazocine;
6         (5) Phencyclidine;
7         (6) Gluthethimide;
8         (7) (Blank).
9     (f) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances:
13         (1) Immediate precursor to amphetamine and
14     methamphetamine:
15             (i) Phenylacetone
16         Some trade or other names: phenyl-2-propanone;
17         P2P; benzyl methyl ketone; methyl benzyl ketone.
18         (2) Immediate precursors to phencyclidine:
19             (i) l-phenylcyclohexylamine;
20             (ii) l-piperidinocyclohexanecarbonitrile (PCC).
21         (3) Nabilone.
22 (Source: P.A. 91-714, eff. 6-2-00.)
 
23     (720 ILCS 570/218 new)
24     Sec. 218. Dextromethorphan.
25     (a) A drug product containing dextromethorphan may not be
26 sold, delivered, distributed, or possessed except in
27 accordance with the prescription requirements of Sections 309,
28 312, and 313 of this Act.
29     (b) A violation of this Section is a Class 4 felony.
30     (c) This Section does not apply to a drug product
31 containing dextromethorphan that is sold in tablet, liquid,
32 capsule, or gel form and which is formulated, packaged, and
33 sold in dosages and concentrations for use as an
34 over-the-counter cough and cold medicine.